Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 in Moderate-to-Severe Atopic Dermatitis
NCT04805411Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Feb 2021
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of stapokibart in atopic dermatitis (AD) (3 arms), sponsored by Keymed Biosciences. Primary endpoint: Proportion of patients achieving at least 75% improvement in Eczema Area and Severity Index at 16 weeks. Started Feb 2021; status: completed.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04805411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04805411.